Adagene(ADAG) GlobeNewswire·2025-01-21 22:00Core Insights - Adagene Inc. is set to present updated clinical data for its drug ADG126 in microsatellite stable colorectal cancer (MSS CRC) at the ASCO Gastrointestinal Cancers Symposium on January 25, 2025 [1][2] Group 1: Clinical Study Details - The Phase 1b/2 study of ADG126 in combination with Merck's KEYTRUDA has shown efficacy at a 10 mg/kg dose, with new data to include results from a 20 mg/kg loading dose followed by 10 mg/kg [2] - The presentation will take place on January 25, 2025, from 7:00 a.m. to 7:55 a.m. Pacific Time at Moscone West, San Francisco, with the abstract number 193 [3] Group 2: Virtual Event Information - A virtual key opinion leader (KOL) event will be hosted on January 25, 2025, featuring experts discussing the treatment landscape for advanced/metastatic MSS CRC and the importance of CTLA-4 targeting [4] Group 3: Company Overview - Adagene Inc. is a clinical-stage biotechnology company focused on developing novel antibody-based cancer immunotherapies, utilizing computational biology and artificial intelligence [5] - The company’s SAFEbody technology aims to improve safety and tolerability of antibody therapeutics by enabling tumor-specific targeting while minimizing off-tumor toxicity [6] - ADG126, the lead clinical program, is a masked anti-CTLA-4 SAFEbody targeting regulatory T cells in the tumor microenvironment, currently in clinical studies for MSS CRC [7]